Table 1.
Mutational analysis in the pretreatment tissue samples and in plasma ctDNA at disease progression.
| Patients Characteristics | Tissue Molecular Analysis (Baseline) | Plasma Molecular Analysis (PD) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt.# | Age | Gender | Smoking Status | ALK | ROS | PD-L1 | KRAS | Other | KRAS (Idylla) |
KRAS (NGS) |
Other |
| 1 | 71 | M | 2 | 0 | 0 | 1 | wt | DDR2 | G12C+ | G12C+ | MAP2K1 |
| 2 | 56 | M | 1 | 0 | 0 | 0 | G12C− | CTNNB1 | wt | wt | BRAFV600E |
| 3 | 65 | M | 2 | 0 | 0 | 0 | wt | None | wt | wt | none |
| 4 | 73 | M | 2 | 0 | 0 | 0 | wt | None | G12C+ | G12C+ | PI3K |
| 5 | 65 | M | 1 | 0 | 0 | 1 | wt | P53 | wt | wt | none |
| 6 | 64 | F | 1 | 0 | 0 | 1 | wt | P53 | G12V | G12V | none |
| 7 | 70 | M | 1 | 0 | 0 | 0 | wt | P53 | G12C+ | G12C+ | MAP2K1 |
| 8 | 77 | F | 2 | 0 | 0 | 1 | G12C− | P53 | wt | wt | P53 |
| 9 | 76 | M | 2 | 0 | 0 | 0 | G12F | p53 | wt | wt | none |
| 10 | 66 | M | 1 | 0 | 0 | 1 | wt | p53; STK11 | G12C+ | G12C+ | EGFR |
| 11 | 65 | M | 1 | 0 | 0 | 1 | wt | P53 | wt | wt | none |
| 12 | 64 | F | 1 | 0 | 0 | 1 | wt | P53 | wt | wt | none |
| 13 | 72 | M | 2 | 0 | 0 | 0 | wt | p53; MET | wt | wt | EGFR |
| 14 | 58 | F | 2 | 0 | 0 | 1 | Q61H | none | wt | wt | none |
| 15 | 72 | F | 2 | 0 | 0 | 1 | wt | none | wt | wt | none |
| 16 | 67 | F | 2 | 0 | 0 | 1 | Q61K | none | wt | wt | none |
| 17 | 77 | F | 2 | 0 | 0 | 0 | wt | AKT | wt | wt | EGFR del 19 |
| 18 | 84 | M | 1 | 0 | 0 | 0 | G12D | STK11 | G12D | G12D | none |
| 19 | 71 | M | 1 | 0 | 0 | 1 | wt | STK11; CTNNB1 | wt | wt | |
| 20 | 44 | M | 2 | 0 | 0 | 0 | wt | none | wt | wt | none |
| 21 | 81 | M | 2 | 0 | 0 | 1 | G12F | p53; NRAS; ERBB4 | G12C+ | G12C+ | P53 |
| 22 | 63 | F | 2 | 0 | 0 | 2 | wt | P53 | wt | wt | PIK3A |
| 23 | 56 | M | 2 | 0 | 0 | 2 | wt | P53 | G12C+ | G12C+ | P53 |
| 24 | 76 | M | 2 | 0 | 0 | 2 | G12C− | none | wt | wt | BRAF V600 |
| 25 | 78 | M | 1 | 0 | 0 | 2 | G12D | none | G12D | G12D | BRAF V600E |
| 26 | 65 | F | 1 | 0 | 0 | 2 | G12D | P53 | G12D | G12D | P53 |
| 27 | 60 | M | 1 | 0 | 0 | 2 | wt | none | G12C+ | G12C+ | BRAFV600 |
| 28 | 65 | F | 0 | 0 | 0 | 2 | wt | none | G12C+ | G12C+ | G12D |
| 29 | 55 | M | 2 | 0 | 0 | 2 | wt | none | wt | wt | MET |
| 30 | 62 | F | 1 | 0 | 0 | 2 | G12C− | none | wt | wt | PIK3A |
| 31 | 69 | M | 2 | 0 | 0 | 2 | G12C− | none | wt | wt | MAP2K1 |
| 32 | 58 | M | 2 | 0 | 0 | 2 | G12C− | none | wt | wt | BRAFv600E |
| 33 | 71 | F | 0 | 0 | 0 | 0 | wt | EGFR; MET | wt | wt | T790M |
| 34 | 60 | M | 0 | 0 | 0 | 2 | wt | EGFR; p53 | wt | wt | T790M |
| 35 | 64 | M | 2 | 1 | 0 | 0 | wt | p53; PIK3A | wt | wt | none |
| 36 | 78 | M | 0 | 0 | 0 | 0 | wt | EGFR; PIK3A | wt | wt | T790M |
| 37 | 87 | M | 2 | 1 | 0 | 2 | wt | none | G12C+ | G12C+ | EGFR |
| 38 | 35 | M | 0 | 0 | 0 | 1 | wt | EGFR | wt | wt | none |
G12C−: patients with the baseline tissue samples positive for the KRAS G12C mutation who became negative in ctDNA at PD. G12C+: patients with the baseline tissue samples negative for the KRAS G12C mutation who acquired a mutation in ctDNA at PD. PD: progressive disease.